Trials / Completed
CompletedNCT05733624
Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis
A Multicenter, Active Control, Parallel Group, Randomized, Double-blind, Phase II Clinical Trial to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops in Patients With Dry Eye Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 116 (actual)
- Sponsor
- SCAI Therapeutics · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This study is planned to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops(Cyclosporine 0.01%, 0.02%) compared to Restasis(Cyclosporine 0.05%) in Patients with Dry Eye Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SCAI-001 0.01% eyedrop | BID for 12weeks |
| DRUG | SCAI-001 0.02% eyedrop | BID for 12weeks |
| DRUG | Restasis 0.05% eyedrop | BID for 12weeks |
Timeline
- Start date
- 2023-01-05
- Primary completion
- 2023-08-23
- Completion
- 2024-02-02
- First posted
- 2023-02-17
- Last updated
- 2024-02-05
Locations
11 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05733624. Inclusion in this directory is not an endorsement.